A provision in the draft Senate legislation on drug pricing may help sponsors of upcoming follow-on biologics applications avoid disaster should their assessment not be completed by the 2020 biologics transition.
A new Senate discussion draft would require any applications assessed under Food Drug and Cosmetic Act Section 505 that...